Dissecting Pivotal Research in Lower-Risk MDS, From ASCO 2025

Guillermo Garcia-Manero, MD, details key updates in lower-risk myelodysplastic syndrome around the 2025 ASCO Annual Meeting.

EP. 1: Recent Shifts in the Management of Lower-Risk MDS

June 19th 2025

Guillermo Garcia-Manero, MD, highlights recent shifts in the lower-risk myelodysplastic syndrome treatment paradigm.

EP. 2: OS Data From COMMANDS for Luspatercept in ESA-Naive, Lower-Risk MDS

June 26th 2025

Guillermo Garcia-Manero, MD, discusses OS data from the COMMANDS trial for luspatercept in ESA-naive, lower-risk MDS.

EP. 3: How Data Are Defining the Role of Luspatercept in ESA-Naive, Lower-Risk MDS

July 10th 2025

Guillermo Garcia-Manero, MD, highlights clinical trial findings and real-world data for luspatercept in ESA-naive, lower-risk MDS.

EP. 4: Integrating Luspatercept Into Clinical Practice and Community Settings in ESA-Naive Lower-Risk MDS

July 22nd 2025

Guillermo Garcia-Manero, MD, discusses the integration of luspatercept into real-world practice in ESA-naive, lower-risk MDS.

EP. 5: Navigating Second-Line Treatment Decisions in Lower-Risk MDS

October 15th 2025

Guillermo Garcia-Manero, MD, discusses second-line treatment decision-making in lower-risk MDS.

EP. 6: Key Areas of Ongoing Research in MDS

October 15th 2025

Guillermo Garcia-Manero, MD, discusses ongoing research to watch in MDS.